Distinct association of serum FGF21 or adiponectin levels with clinical parameters in patients with type 2 diabetes

被引：50

作者：

Eto, Kazuhiro ^{[1
,2
]}

Tumenbayar, Bayasgalan ^{[2
]}

Nagashima, Shu-ichi ^{[2
]}

Tazoe, Fumiko ^{[2
]}

Miyamoto, Michiaki ^{[2
]}

Takahashi, Manabu ^{[2
]}

Ando, Akihiko ^{[2
]}

Okada, Kenta ^{[2
]}

Yagyu, Hiroaki ^{[2
]}

Ishibashi, Shun ^{[2
]}

机构：

[1] Teikyo Univ, Sch Med, Dept Internal Med, Itabashi Ku, Tokyo 1738605, Japan

[2] Jichi Med Univ, Dept Med, Div Endocrinol & Metab, Shimotsuke, Tochigi 3290498, Japan

来源：

DIABETES RESEARCH AND CLINICAL PRACTICE | 2010年 / 89卷 / 01期

关键词：

FGF21; Adiponectin; Type; 2; diabetes; ACTIVATED-RECEPTOR-GAMMA; PPAR-ALPHA; FIBROBLAST-GROWTH-FACTOR-21; MELLITUS; FGF-21; IDENTIFICATION; METABOLISM; REGULATOR; DISEASES; KLOTHO;

D O I：

10.1016/j.diabres.2010.03.019

中图分类号：

R5 [内科学];

学科分类号：

100201 [内科学];

摘要：

Fibroblast growth factor 21 (FGF21) has been identified as a novel metabolic regulator. This cross-sectional study was performed to clarify how serum FGF21 levels were associated with clinical parameters in Japanese subjects with type 2 diabetes (n = 139). Anthropometric and blood biochemical parameters, uses of drugs for diabetes, hypertension and dyslipidemia were examined regarding associations with fasting serum FGF21 concentrations. FGF21 levels were 6-times higher in those subjects taking fibrates. However, a use of thiazolidinediones did not affect serum FGF21 levels while it induced higher serum adiponectin levels. In univariate analyses, FGF21 levels showed associations with a use of fibrates, triglyceride levels, creatinine levels, waist circumference, and BMI. Multiple regression analyses adjusted for age, gender and BMI showed that a use of fibrates, triglyceride levels and creatinine levels were strong contributors to serum FGF21 levels. In contrast, a use of thiazolidinediones, HDL-cholesterol levels and fasting insulin levels were strong contributors to serum adiponectin levels. This study revealed that serum FGF21 levels were biochemical indicators correlating to a set of essential metabolic parameters, which was distinct from that correlating to serum adiponectin levels in subjects with type 2 diabetes. (C) 2010 Elsevier Ireland Ltd. All rights reserved.

引用

页码：52 / 57

页数：6

共 25 条

[1]

Badman MK, 2007, CELL METAB, V5, P426, DOI 10.1016/j.cmet.2007.05.002

[2]

Circulating FGF-21 levels in normal subjects and in newly diagnose patients with type 2 diabetes Mellitus [J].

Chen, W. -W. ;

Li, L. ;

Yang, G. -Y. ;

Li, K. ;

Qi, X. -Y. ;

Zhu, W. ;

Tang, Y. ;

Liu, H. ;

Boden, G. .

EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2008, 116 (01) :65-68

[3]

Fruchart JC, 2008, AM J CARDIOL, V102, p1K, DOI [10.1016/j.amjcard.2008.10.002, 10.1016/S0002-9149(08)01833-X]

[4]

HOJMAN P, 2009, FIBROBLAST GROWTH FA

[5]

The fasting polypeptide FGF21 can enter brain from blood [J].

Hsuchou, Hung ;

Pan, Weihong ;

Kastin, Abba J. .

PEPTIDES, 2007, 28 (12) :2382-2386

[6]

Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis [J].

Inagaki, T ;

Choi, M ;

Moschetta, A ;

Peng, L ;

Cummins, CL ;

McDonald, JG ;

Luo, G ;

Jones, SA ;

Goodwin, B ;

Richardson, JA ;

Gerard, RD ;

Repa, JJ ;

Mangelsdorf, DJ ;

Kliewer, SA .

CELL METABOLISM, 2005, 2 (04) :217-225

[7]

Endocrine regulation of the fasting response by PPARα-mediated induction of fibroblast growth factor 21 [J].

Inagaki, Takeshi ;

Dutchak, Paul ;

Zhao, Guixiang ;

Ding, Xunshan ;

Gautron, Laurent ;

Parameswara, Vinay ;

Li, Yong ;

Goetz, Regina ;

Mohammadi, Moosa ;

Esser, Victoria ;

Elmquist, Joel K. ;

Gerard, Robert D. ;

Burgess, Shawn C. ;

Hammer, Robert E. ;

Mangelsdorf, David J. ;

Kliewer, Steven A. .

CELL METABOLISM, 2007, 5 (06) :415-425

[8]

FGF21 is an Akt-regulated myokine [J].

Izumiya, Yasuhiro ;

Bina, Holly A. ;

Ouchi, Noriyuki ;

Akasaki, Yuichi ;

Kharitonenkov, Alexei ;

Walsh, Kenneth .

FEBS LETTERS, 2008, 582 (27) :3805-3810

[9]

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study):: randomised controlled trial [J].

Keech, A ;

Simes, RJ ;

Barter, P ;

Best, J ;

Scott, R ;

Taskinen, MR ;

Forder, P ;

Pillai, A ;

Davis, T ;

Glasziou, P ;

Drury, P ;

Kesäniemi, YA ;

Sullivan, D ;

Hunt, D ;

Colman, P ;

d'Emden, M ;

Whiting, M ;

Ehnholm, C ;

Laakso, M .

LANCET, 2005, 366 (9500) :1849-1861

[10]

FGF-21 as a novel metabolic regulator [J].

Kharitonenkov, A ;

Shiyanova, TL ;

Koester, A ;

Ford, AM ;

Micanovic, R ;

Galbreath, EJ ;

Sandusky, GE ;

Hammond, LJ ;

Moyers, JS ;

Owens, RA ;

Gromada, J ;

Brozinick, JT ;

Hawkins, ED ;

Wroblewski, VJ ;

Li, DS ;

Mehrbod, F ;

Jaskunas, SR ;

Shanafelt, AB .

JOURNAL OF CLINICAL INVESTIGATION, 2005, 115 (06) :1627-1635

← 1 2 3 →